FDAnews
www.fdanews.com/articles/132367-advisory-panel-favors-astrazeneca-8217-s-thyroid-cancer-drug-zictifa

Advisory Panel Favors AstraZeneca’s Thyroid Cancer Drug Zictifa

December 3, 2010
An FDA advisory committee has given its support to AstraZeneca’s thyroid cancer treatment Zictifa, saying agency concerns about the drug’s safety were not enough to justify limiting its indication. While FDA drug reviewers had focused on Zictifa’s (vandetanib) “substantial toxicity profile,” members of the agency’s Oncologic Drugs Advisory Committee said physicians would be able to determine the appropriate use of the drug for their patients.
Drug Industry Daily